238 Trial - Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy - 100459

Spotlight
Video

238 Trial - Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy

moasc has 295 videos Subscribe Here

Loading........
Description: Omid Hamid MD
Chief, Translational Research/Immuno-Oncology
Director explains, 238 Trial - Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy at the 2018 Oncology Summit in Huntington Beach, CA
Shared By : moasc
Posted on : 03/08/18
Added : 4 months ago



Recommended

Nothing found.